[go: up one dir, main page]

NO863974D0 - Monoklonale antihuman brystkreftantistoffer. - Google Patents

Monoklonale antihuman brystkreftantistoffer.

Info

Publication number
NO863974D0
NO863974D0 NO863974A NO863974A NO863974D0 NO 863974 D0 NO863974 D0 NO 863974D0 NO 863974 A NO863974 A NO 863974A NO 863974 A NO863974 A NO 863974A NO 863974 D0 NO863974 D0 NO 863974D0
Authority
NO
Norway
Prior art keywords
breast cancer
cancer antibodies
imaging
tumors
monoclonal
Prior art date
Application number
NO863974A
Other languages
English (en)
Other versions
NO863974L (no
Inventor
David B Ring
Arthur E Frankel
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of NO863974D0 publication Critical patent/NO863974D0/no
Publication of NO863974L publication Critical patent/NO863974L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/804—Drug, bio-affecting and body treating compositions involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y10S424/807—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Geophysics And Detection Of Objects (AREA)
  • Navigation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO863974A 1985-10-07 1986-10-06 Monoklonale antihuman brystcanser antistoffer. NO863974L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78507685A 1985-10-07 1985-10-07
US06/786,948 US4938948A (en) 1985-10-07 1985-10-11 Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies

Publications (2)

Publication Number Publication Date
NO863974D0 true NO863974D0 (no) 1986-10-06
NO863974L NO863974L (no) 1987-04-08

Family

ID=27120360

Family Applications (1)

Application Number Title Priority Date Filing Date
NO863974A NO863974L (no) 1985-10-07 1986-10-06 Monoklonale antihuman brystcanser antistoffer.

Country Status (13)

Country Link
US (1) US4938948A (no)
EP (1) EP0220858B1 (no)
JP (3) JP2968474B2 (no)
AT (1) ATE85652T1 (no)
AU (1) AU6356986A (no)
CA (1) CA1338706C (no)
DE (1) DE3687736T2 (no)
DK (1) DK478886A (no)
ES (1) ES2053440T3 (no)
FI (1) FI864037A (no)
IL (1) IL80231A (no)
NO (1) NO863974L (no)
NZ (1) NZ217829A (no)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5032521A (en) * 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
AU601379B2 (en) * 1985-11-07 1990-09-13 Trustees Of Columbia University In The City Of New York, The Antigen indicative of human breast cancer and assays based thereon
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US6861511B1 (en) 1986-06-04 2005-03-01 Bayer Corporation Detection and quantification of neu related proteins in the biological fluids of humans
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
NZ222509A (en) * 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US6004761A (en) * 1986-11-19 1999-12-21 Sanofi Method for detecting cancer using monoclonal antibodies to new mucin epitopes
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5084266A (en) * 1988-02-03 1992-01-28 The University Of Melbourne Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5849877A (en) * 1990-10-29 1998-12-15 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5948647A (en) * 1990-10-29 1999-09-07 Chiron Corporation Nucleic acids encoding antigen-binding sites specific for cancer antigens
US5811267A (en) * 1990-10-29 1998-09-22 Chiron Corporation Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
US5292524A (en) * 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
WO1993016185A2 (en) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US7255851B2 (en) * 1994-07-01 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US20030086922A1 (en) * 1994-12-02 2003-05-08 David B. Ring Method of promoting an immune response with a bispecific antibody
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
GB9906380D0 (en) * 1999-03-19 1999-05-12 Melvin William T Monoclonal antibodies specific for cypibi
FR2811323B1 (fr) * 2000-07-07 2006-10-06 Fuma Tech Gmbh Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
DE10141937A1 (de) * 2001-08-28 2003-03-27 Alfred Schmidt Markierung der Aromatase
ATE443259T1 (de) 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040023267A1 (en) * 2002-03-21 2004-02-05 Morris David W. Novel compositions and methods in cancer
AU2003304195B8 (en) 2002-07-15 2008-08-28 Board Of Regents, The University Of Texas System Combinatorial protein library screening by periplasmic expression
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
EP2058408A3 (en) 2003-02-14 2009-09-09 Sagres Discovery, Inc. Therapeutic GPCR targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
US20050214286A1 (en) * 2004-01-27 2005-09-29 University Of Southern California Polymer-bound antibody cancer therapeutic agent
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
EP1802313B1 (en) 2004-09-18 2010-11-03 University of Maryland, Baltimore Therapeutic agents trageting the ncca-atp channel and methods of use thereof
AU2005287090A1 (en) 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
PT3264094T (pt) 2005-04-04 2020-11-24 Biogen Ma Inc Método para avaliar uma resposta imune a um agente terapêutico
WO2006110599A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cacna1e in cancer diagnosis, detection and treatment
WO2006110585A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes (prlr)
DE212006000071U1 (de) 2005-11-18 2008-07-24 Board of Regents, The University of Texas System, Austin Quantifizierung von Fusionsproteinen und ihrer Aktivität in Folge chromosomaler Translokation
WO2008005429A2 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
US8067179B2 (en) 2006-11-30 2011-11-29 Research Development Foundation Immunoglobulin libraries
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
KR100855299B1 (ko) * 2007-02-16 2008-08-29 건국대학교 산학협력단 인간 ｉｌ-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 ｉｌ-32측정법
WO2008137475A2 (en) 2007-05-01 2008-11-13 Research Development Foundation Immunoglobulin fc libraries
GB2451928B (en) * 2007-06-21 2011-03-16 Angelica Therapeutics Inc Modified Toxins
WO2009020923A1 (en) 2007-08-03 2009-02-12 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
MX2010007530A (es) 2008-01-10 2010-11-10 Res Dev Foundation Vacunas y diagnosticos para ehrlichiosis.
WO2009110944A1 (en) 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
EP2350131B1 (en) 2008-11-07 2017-06-07 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
US20110287088A1 (en) 2008-12-03 2011-11-24 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP3349010B1 (en) 2009-10-11 2024-08-28 Biogen MA Inc. Anti-vla-4 related assays
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
AU2012214643B2 (en) 2011-02-07 2016-12-15 Research Development Foundation Engineered immunoglobulin Fc polypeptides
KR102101160B1 (ko) 2011-04-01 2020-04-16 이뮤노젠 아이엔씨 Folr1 암 치료의 효능을 증가시키기 위한 방법
CA2842971C (en) 2011-08-05 2019-11-12 Research Development Foundation Improved methods and compositions for modulation of olfml3 mediated angiogenesis
CN103906535B (zh) 2011-08-15 2017-07-14 芝加哥大学 与葡萄球菌蛋白a的抗体相关的组合物和方法
ES2731757T3 (es) 2012-03-20 2019-11-18 Biogen Ma Inc Anticuerpos neutralizantes de JCV
CN104703622B (zh) 2012-04-26 2017-05-24 芝加哥大学 与金黄色葡萄球菌疾病期间抵消凝固酶活性的抗体相关的组合物和方法
AU2013260123A1 (en) 2012-05-10 2014-11-13 Massachusetts Institute Of Technology Agents for influenza neutralization
KR20200102524A (ko) 2012-08-07 2020-08-31 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP2912064B1 (en) 2012-10-24 2019-04-24 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
WO2014127211A1 (en) 2013-02-15 2014-08-21 Research Development Foundation Deimmunized gelonin molecules and therapies
EP2970909A4 (en) 2013-03-15 2017-02-15 The University of Chicago Methods and compositions related to t-cell activity
WO2014150600A2 (en) 2013-03-15 2014-09-25 Angelica Therapeutics, Inc. Modified toxins
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
CA2905986A1 (en) 2013-03-15 2014-09-25 Bayer Healthcare Llc Gla domains as therapeutic agents
US10526375B2 (en) 2013-06-05 2020-01-07 Massachusetts Institute Of Technology Human Adaptation of H7 HA
AU2014302082B2 (en) 2013-06-28 2019-08-08 Baylor Research Institute Dendritic cell ASGPR targeting immunotherapeutics for multiple sclerosis
AU2014308699C1 (en) 2013-08-21 2022-06-02 Board Of Regents, The University Of Texas System Compositions and methods for targeting connexin hemichannels
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
US20170002064A1 (en) 2013-11-08 2017-01-05 The Board Of Regents Of The University Of Texas System Vh4 antibodies against gray matter neuron and astrocyte
CA2936833A1 (en) 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
US10059775B2 (en) 2014-01-29 2018-08-28 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
US9902764B2 (en) 2014-02-11 2018-02-27 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
DK3140653T3 (da) 2014-05-08 2022-06-20 Novodiax Inc Direkte immunhistokemianalyse
WO2015179435A1 (en) 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
KR102485788B1 (ko) 2014-08-27 2023-01-09 메모리얼 슬로안 케터링 캔서 센터 항체, 조성물 및 용도
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
AU2016219511B2 (en) 2015-02-09 2020-11-12 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation
WO2016130539A2 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
CA2977499C (en) 2015-02-25 2023-10-03 Vanderbilt University Antibody-mediated neutralization of marburg virus
WO2017040380A2 (en) 2015-08-28 2017-03-09 Research Development Foundation Engineered antibody fc variants
SI3373968T1 (sl) 2015-11-09 2024-10-30 The Children's Hospital Of Philadelphia Glipikan 2 kot marker raka in terapevtska tarča
CN109415437B (zh) 2015-12-02 2022-02-01 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
WO2017096017A1 (en) 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
EP3383418B1 (en) 2015-12-04 2021-10-20 Board of Regents, The University of Texas System Slc45a2 peptides for immunotherapy
US10889637B2 (en) 2016-02-26 2021-01-12 The Board Of Regents Of The University Of Texas System Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies
EP3436481B1 (en) 2016-03-29 2021-06-30 Stcube, Inc. Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
US11559590B2 (en) 2016-07-01 2023-01-24 The General Hospital Corporation Granzyme B directed imaging and therapy
JP2019528251A (ja) 2016-07-20 2019-10-10 エスティーキューブ，インコーポレイテッド グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法
EP3534953A4 (en) 2016-11-02 2020-10-07 Vanderbilt University ANTIBODIES AGAINST HUMAN ZIKA VIRUS AND THEIR USE PROCEDURES
WO2018126183A2 (en) 2016-12-29 2018-07-05 The General Hospital Corporation Her3 peptides for imaging and radiotherapy
CA3051466A1 (en) 2017-01-31 2018-08-09 Vanderbilt University Generation of human allergen-and helminth-specific ige monoclonal antibodies for diagnostic and therapeutic use
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
CR20200138A (es) 2017-08-25 2020-06-14 Five Prime Therapeutics Inc Anticuerpos de b7-h4 y métodos para usarlos
CN111051500A (zh) 2017-09-05 2020-04-21 角斗士生物科学公司 有效载荷递送至干细胞
GB2581619A (en) 2017-09-15 2020-08-26 Univ California Inhibition of aminoacylase 3 (AA3) in the treatment of cancer
CN118459413A (zh) 2017-09-26 2024-08-09 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
EP4116327A1 (en) 2017-10-11 2023-01-11 Board Of Regents, The University Of Texas System Human pd-l1 antibodies and methods of use therefor
EP3735589A2 (en) 2018-01-05 2020-11-11 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
EP3759142A1 (en) 2018-03-02 2021-01-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
US12187799B2 (en) 2018-03-23 2025-01-07 Board Of Regents, The University Of Texas System Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor
AU2019339469A1 (en) 2018-09-13 2021-03-11 Immune-Onc Therapeutics, Inc. Novel LILRB4 antibodies and uses thereof
KR20210108363A (ko) 2018-11-02 2021-09-02 오클라호마 메디컬 리써치 화운데이션 Eltd1에 대한 단일클론성 항체 및 이의 용도
CN113423465B (zh) 2018-11-28 2024-12-06 俄勒冈健康与科学大学 治疗性的因子xii抗体
WO2020167989A1 (en) 2019-02-13 2020-08-20 Cytosite Biopharma Inc. Granzyme b directed imaging and therapy
US20220257653A1 (en) 2019-07-19 2022-08-18 The Children's Hospital Of Philadelphia Chimeric antigen receptors containing glypican 2 binding domains
JP2022541652A (ja) 2019-07-26 2022-09-26 ヴァンダービルト ユニバーシティ エンテロウイルスｄ６８に対するヒトモノクローナル抗体
KR20220088428A (ko) 2019-09-26 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
US20220356248A1 (en) 2019-10-09 2022-11-10 Stcube & Co Antibodies specific to glycosylated lag3 and methods of use thereof
JP2023519105A (ja) 2020-02-11 2023-05-10 ヴァンダービルト ユニバーシティ 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）に対するヒトモノクローナル抗体
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
AU2021242306A1 (en) 2020-03-26 2022-11-17 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
GB202105804D0 (en) 2020-11-20 2021-06-09 Univ Cape Town Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
WO2022192134A1 (en) 2021-03-08 2022-09-15 Immunogen, Inc. Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2023192976A1 (en) 2022-04-01 2023-10-05 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
IL317568A (en) 2022-06-10 2025-02-01 Res Found Dev Engineered FCRIIB Selective IgG1 FC Variants, and Their Uses
WO2024040020A1 (en) 2022-08-15 2024-02-22 Absci Corporation Quantitative affinity activity specific cell enrichment
WO2024188356A1 (en) 2023-03-16 2024-09-19 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Ilt7-targeting antibodies and uses thereof
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies
WO2024213648A1 (en) 2023-04-11 2024-10-17 Sterling Ip Pte. Ltd. Treatment of haematological cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
DE3483054D1 (de) * 1983-03-04 1990-10-04 Health Research Inc Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
WO1985001442A1 (en) * 1983-09-28 1985-04-11 Summa Medical Corporation Lectin composition and method for diagnosis of cancer
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
DE3586216T2 (de) * 1984-05-01 1992-12-10 Ciba Corning Diagnostics Corp Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
US4695538A (en) * 1984-06-01 1987-09-22 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cell surface antigens
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies

Also Published As

Publication number Publication date
DK478886D0 (da) 1986-10-07
EP0220858A3 (en) 1988-08-03
NZ217829A (en) 1989-06-28
US4938948A (en) 1990-07-03
JP2000000091A (ja) 2000-01-07
JP2000000092A (ja) 2000-01-07
JPH08266273A (ja) 1996-10-15
FI864037A (fi) 1987-04-08
JP2968474B2 (ja) 1999-10-25
DE3687736D1 (de) 1993-03-25
IL80231A (en) 1991-08-16
ATE85652T1 (de) 1993-02-15
CA1338706C (en) 1996-11-12
DE3687736T2 (de) 1993-05-27
EP0220858A2 (en) 1987-05-06
NO863974L (no) 1987-04-08
ES2053440T3 (es) 1994-08-01
AU6356986A (en) 1987-04-09
DK478886A (da) 1987-04-08
FI864037A0 (fi) 1986-10-06
EP0220858B1 (en) 1993-02-10

Similar Documents

Publication Publication Date Title
NO863974D0 (no) Monoklonale antihuman brystkreftantistoffer.
ES8705975A1 (es) Un metodo de deteccion o localizacion de celulas de carcinoma humano.
DK25084A (da) Human-human hybridoma mod neoplasmer
EP0597829A4 (en) NEW MONOCLONAL ANTIBODY DRESSES AGAINST A NEW ANTIGEN ASSOCIATED WITH HUMAN TUMORS.
ATE101202T1 (de) Antikoerper.
NZ222309A (en) Antibodies (including chimeric antibodies) to a human tumour antigen, polynucleotides encoding them, detection of the antigen by immunoassay and imaging methods and also cell killing methods
DE3751908D1 (de) Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
YU48442B (sh) Postupak za dobivanje monoklonalnog antitela okt 3
DE3483054D1 (de) Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
ATE205532T1 (de) Zellzyklus-unabhängige, gliomaoberflach- spezifische, menschliche monoklonale antikörper
EP0232871A3 (en) Human monoclonal antibody, hybridoma producing the same and its use
EP0155172A3 (en) Anti-human lung cancer monoclonal antibodies
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
DE3784364D1 (de) Tumorassoziiertes antigen.
JPS6444856A (en) Anti-cancer antigen anti-serum
Hand et al. Potential Clinical Application of a Monoclonal Antibody to a Tumor Associated Glycoprotein (TAG-72)
ATE74213T1 (de) Monoklonale antikoerper mit bindungsspezifitaet fuer menschliche prostatatumorantigene und methoden fuer ihre verwendung.
ATE17190T1 (de) Mittel zur tumorlokalisierung und therapie mit markierten antikoerpern und antikoerperfragmenten.